Device/Diagnostics Quarterly Deal-Making Statistics, Q4 2017

A look at the financing, M&A and alliance activity in October–December 2017

Device fundraising during the fourth quarter totaled $2.6 billion, making it the strongest quarter of the year. Q4 M&A activity reached $3.9 billion, higher than Q3's $3.4 billion, but still one of the lowest quarters of the year. Both fourth quarter diagnostics financings and M&As hit an all-year low of $622 million, and $2.8 million, respectively.

Quarterly Stats_1200x675

Device fundraising in Q4 2017 totaled $2.6 billion, the highest single-quarter value of the year. However, total 2017 financing for the industry declined from 2016: $8.4 billion in 2017 compared with $8.9 billion from the previous year. This wasn't a significant decline, but a decline nonetheless. One major difference in 2017 was notably less money coming in from IPOs – in 2016, companies raised $2 billion through IPOs, exponentially more than 2017's $175 million (but approximately $1.8 billion in 2016 was from a single IPO transaction, by ConvaTec Inc.[See Deal]). In 2017, debt offerings gradually grew in value, reaching well over $1 billion in the final two quarters. In contrast, there was a notable decline in early-stage financings, which totaled $990 million in Q1, but slowed down to just $152 million in Q4, although the majority of the Q1 figure was from Verily Life Sciences LLC's $800 million Series A round from Temasek [See Deal]. (See Exhibit 1.)

Exhibi

More from Deal-Making

More from In Vivo

Plans For London Cancer Hub Promises New Destination For Biotech Innovation

 
• By 

Plans have been submitted for a £1bn development in London that can home biotech companies and encourages cross collaboration with the Institute of Cancer Research. In Vivo took an exclusive tour of the UK’s prospective new cancer innovation district.

Califf In Conversation: “Decimated” FDA Teams Endanger Biologics Progress

 

In Vivo spoke to the previous commissioner of the US FDA about recent ongoings at the agency, and where he believes policy should be directed for patient and industry benefit.

Rising Leaders 2025: Rob Barrow On Leading MindMed’s Psychedelic Renaissance

 
• By 

Rob Barrow's unconventional journey from finance to leading MindMed highlights his innovative approach to psychedelic medicine, aiming to transform mental health treatment with groundbreaking therapies.